An (R)‐Imine Reductase Biocatalyst for the Asymmetric Reduction of Cyclic Imines. Issue 4 (21st January 2015)

• Record Type: Journal Article
• Authors: Hussain, Shahed; Leipold, Friedemann; Man, Henry; Wells, Elizabeth; France, Scott P.; Mulholland, Keith R.; Grogan, Gideon; Turner, Nicholas J.
• Is Part Of: ChemCatChem. Volume 7:Issue 4(2015:Feb.)
• Page Start: 579
• Page End: 583
• Publication Date: 2015-01-21
• Subjects: Catalysis -- Periodicals; 541.39505
• DOI: 10.1002/cctc.201402797
• Languages: English
• ISSNs: 1867-3880

Abstract

<abstract abstract-type="main" xml:lang="en"> <title>Abstract</title> <p>Although the range of biocatalysts available for the synthesis of enantiomerically pure chiral amines continues to expand, few existing methods provide access to secondary amines. To address this shortcoming, we have over‐expressed the gene for an (<italic>R</italic>)‐imine reductase [(<italic>R</italic>)‐IRED] from <italic>Streptomyces</italic> sp. GF3587 in <italic>Escherichia coli</italic> to create a recombinant whole‐cell biocatalyst for the asymmetric reduction of prochiral imines. The (<italic>R</italic>)‐IRED was screened against a panel of cyclic imines and two iminium ions and was shown to possess high catalytic activity and enantioselectivity. Preparative‐scale synthesis of the alkaloid (<italic>R</italic>)‐coniine (90 % yield; 99 % <italic>ee</italic>) from the imine precursor was performed on a gram‐scale. A homology model of the enzyme active site, based on the structure of a closely related (<italic>R</italic>)‐IRED from <italic>Streptomyces kanamyceticus</italic>, was constructed and used to identify potential amino acids as targets for mutagenesis.</p> </abstract>